Restricted HIV-1 diversity and clonal expansion following cytoreductive chemotherapy von Henrich, T.J., Scully, E.P., Hobbs, K.S., Hanhauser, E., Hogan, L.E., Palmer, C.D., Robles, Y.P., Leadabrand, K.S., LaCasce, A.S., Kuritzkes, D.R.

Volltext

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis von Barnes, J.A., LaCasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P., Abramson, J.S.

Volltext

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma von Barnes, J.A., LaCasce, A.S., Zukotynski, K., Israel, D., Feng, Y., Neuberg, D., Toomey, C.E., Hochberg, E.P., Canellos, G.P., Abramson, J.S.

Volltext

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy von Sher, D. J., Mauch, P. M., Van Den Abbeele, A., LaCasce, A. S., Czerminski, J., Ng, A. K.

Volltext

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND β‐GLUCAN PGG IN RELAPSED/REFRACTORY INDOLENT B‐CELL NON‐HODGKIN LYMPHOMA von Jacobson, C.A., Redd, R., Reynolds, C., Fields, M., Armand, P., Fisher, D.C., Jacobsen, E.D., LaCasce, A.S., Bose, N., Ottoson, N., Freedman, A.

Volltext

INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA von Herrera, A.F., Moskowitz, A.J., Bartlett, N.L., Vose, J.M., Ramchandren, R., Feldman, T.A., Lacasce, A.S., Ansell, S.M., Moskowitz, C.H., Fenton, K., Ogden, C., Taft, D., Zhang, Q., Kato, K., Campbell, M., Advani, R.H.

Volltext

A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) von Caimi, P.F., Eder, J.P., Jacobsen, E.D., Jacobson, C.A., LaCasce, A.S., Shipp, M.A., Chapuy, B., Labriola‐Tomphins, E., Boisserie, F., Passe, S., Chesné, E., Pierceall, W., Zhi, J., DeMario, M., Vaishampayan, U., Dowlati, A., Shapiro, G.I., Fisher, D.C., Armand, P.

Volltext

PF374 IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE‐ARM, MULTICENTER, PHASE... von Davids, M.S., Brander, D.M., Kim, H.T., Tyekucheva, S., Bsat, J., Savell, A., Hellman, J.M., Bazemore, J., Francoeur, K., Alencar, A., Shune, L., Omaira, M., Jacobson, C.A., Armand, P., Ng, S., Crombie, J., LaCasce, A.S., Arnason, J., Hochberg, E.P., Takvorian, R.W., Abramson, J.S., Fisher, D.C., Brown, J.R.

Volltext

(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma von Abou-Nassar, K E, Stevenson, K E, Antin, J H, McDermott, K, Ho, V T, Cutler, C S, LaCasce, A S, Jacobsen, E D, Fisher, D C, Soiffer, R J, Alyea, E P, Koreth, J, Freedman, A S

Volltext

54: Inclusion of Sirolimus in the GVHD Prophylaxis Regimen is Associated with Improved Survival in Patients with Lymphoma Undergoing Allogeneic Transplantation von Armand, P, Gannamaneni, S, Kim, H.T, Cutler, C.S, Ho, V.T, Koreth, J, Alyea, E.P, LaCasce, A.S, Jacobsen, E.D, Fisher, D.C, Brown, J.R, Canellos, G.P, Freedman, A.S, Soiffer, R.J, Antin, J.H

Volltext